Business
Sunshine Biopharma Reports Improved Cash Position in 2021Q1 Filing
MONTREAL, May 13, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development, and
About this update from Sunshine Biopharma Inc.
[{"type":"text","content":"MONTREAL, May 13, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs, announced that it has filed its 2021 first quarter report. The Report shows that the Company had Cash & Cash Equivalents of $1,796,596 as of March 31, 2021, the period end. The following is a summary of the Report highlights: On January 26, 2021, the Company received a Notice of Allowance from the Canadian Intellectual Property Office for a new patent application covering Adva-27a. The newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033. On February 4, 2021, the Company entered into an exclusive license agreement with the University of Georgia (“UGA”) for two Anti-Coronavirus compounds which UGA had previously developed and patented. The Company and UGA will advance the development of these two compounds in parallel with the Company’s own Anti-Coronavirus compound, SBFM-PL4. On March 1, 2021, the Company launched a new eCommerce website, Nutrition.SunshineBiopharma.com. The site offers over 20 Science-Based Nutritional Supplements products ranging from essential amino acids and rich protein powders to balanced vitamins and crucial micronutrients. All of the Company’s Science-Based Nutritional Supplements are manufactured and tested in Canada under GMP conditions. On March 9, 2021, the Company received a Notice of Allowance from the European Patent Office for a new patent application covering Adva-27a. The newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued in 2019 (US Patent Number 10,272,065). Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are incredibly pleased with the progress of our Company as a whole. We continue to receive positive interim results from the University of Georgia regarding our mice study and the development of our Anti-Coronavirus treatment, and are very happy about our expanded patents for Adva-27a.” About Sunshine Biopharma’s Coronavirus (COVID-19) Treatment Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3....